Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|1|37-45

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.1, 2010-02, pp. : 37-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer

By Meulenbeld Hielke J.   Creemers Geert-Jan  

Drugs & Aging, Vol. 24, Iss. 3, 2007-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite

Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer: State of the Art

By Diasio Robert B.   Fourie Jeanne  

Drugs, Vol. 66, Iss. 11, 2006-01 ,pp. : 1441-1463

Adis International

Access to resources Recommend Favorite

First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer

By Gill S.  

Drugs, Vol. 64, Iss. 1, 2004-01 ,pp. : 27-44

Adis International

Access to resources Recommend Favorite

Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer

By Scott Lesley J.  

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1793-1799

Adis International

Access to resources Recommend Favorite

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite